Actively Recruiting
Study of Pegfilgrastim to Prevent Febrile Neutropenia in Adults with Triple-Negative Breast Cancer Receiving AC Chemotherapy After Paclitaxel and Carboplatin
Led by Yonsei University · Updated on 2026-04-20
40
Participants Needed
2
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the use of pegfilgrastim to prevent febrile neutropenia FN in adults with triple-negative breast cancer TNBC undergoing a specific chemotherapy regimen. This regimen includes anthracyclinecyclophosphamide AC chemotherapy following neoadjuvant treatment with paclitaxel and carboplatin. The study aims to gather real-world evidence on the safety and effectiveness of pegfilgrastim in this setting, as current data for Korean patients are limited. Participants will receive pegfilgrastim 6 mg as a subcutaneous injection once per cycle on Day 2, about 24 hours after completing each AC chemotherapy cycle. This treatment is given during four cycles of AC chemotherapy. The study is open-label and single-arm, meaning all participants receive the same treatment without placebo comparison. During the study, participants will be monitored for the occurrence of febrile neutropenia and other blood-related side effects. Researchers will track hospitalization rates related to FN, severe neutropenia, and any chemotherapy delays or dose reductions caused by neutropenia. Safety evaluations, including hematologic and non-hematologic toxicities, will continue for up to six months after treatment. The study period covers up to 12 weeks for primary outcomes and includes follow-up for safety assessments.
CONDITIONS
Brief Title
An Open-label Prospective Study to Evaluate the Efficacy and Safety of Pegfilgrastim in Triple-Negative Breast Cancer Patients Receiving AC Regimen Following Paclitaxel and Carboplatin as Neoadjuvant Therapy
Research Team
G
Gun Min Kim, Professor
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here